Pro Medicus Limited (PMDIY) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Pro Medicus Limited $8.94, price $23.35, upside -61.7%, quality 83 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Pro Medicus Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
29‑month range $13.18 – $45.59 · fair‑value band $5.36 – $19.78 · the $23.35 price screens above the $8.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Pro Medicus in your weekly email
Every Wednesday you see whether Pro Medicus is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe.
Show more
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease, a mobile application that provides users access to medical imaging results; and Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
Stock analysis
Pro Medicus Limited (PMDIY) currently trades at $23.35, while our model-based Fair Value estimate is $8.94, 61.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $6.55 per share, and 0 of the 20 models we run sit above the $23.35 price.
Bear case: the Multiples group reads lowest at $1.54, and 20 of the 20 models stay below the price. Evidence for this calculation is medium.
Scenario range: $5.36 (bear) to $19.78 (bull), the price of $23.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 83/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Pro Medicus Limited reported revenue of A$213M in FY2025 versus A$93.4M in FY2022, a compound +31.6%/yr. Reported net income was A$115M in FY2025, compounding +37.4%/yr from FY2022.
Key figures
Market cap $12.3B · P/E ratio 73.0 · P/S ratio 39.5 · EPS (TTM) $0.3200 · Dividend yield 0.4% · Net margin 54.1% · Return on equity 76.8% · Return on assets (EBIT) 42.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (medium confidence).
What moves the price
The share trades about 41% below its 52-week high and 64% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −62%, PMDIY screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($0.2300 to $7.28). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $5.36Fair Value $8.94Bull $19.78
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.88/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+31.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.6%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+37.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+36.9%
Dividend (yield on the price)0.4%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.67% → 74%
2025 sits 90% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+21.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +4.7% a year for the price and +18.9% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 128 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score83 · Top 25%
Fair Value upside−45.9% · Below median
Profitability
Return on equity (TTM)76.8% · Top 25%
Return on assets27.0% · Top 25%
Net margin (TTM)97.6% · Top 25%
Operating margin (TTM)72.7% · Top 25%
Growth and dividend
Revenue growth28.4% · Top 25%
Dividend yield (TTM)0.4% · Bottom 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (TTM)73.0× · Priciest 25%
P/B47.79× · Priciest 25%
P/S (TTM)51.05× · Priciest 25%
P/FCF118.1× · Priciest 25%
EV/EBITDA67.7× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 41
PAST (return on equity)100· sector 8
HEALTH (low debt)0· sector 98
DIVIDEND (yield)7· sector 44
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pro Medicus Limited Fair Value". https://www.fairvalue-calculator.com/stock/PMDIY
Frequently asked questions
Is Pro Medicus Limited (PMDIY) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $8.94 versus the last price from Sep 25, 2026 of $23.35, about −62% upside (overvalued).
What is the fair value of PMDIY?
Our model-based fair value for Pro Medicus Limited is $8.94 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $23.35.
What is the quality score of PMDIY?
Pro Medicus Limited has a Quality Score of 83/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pro Medicus Limited (PMDIY)?
Our model-based price target is the fair value of $8.94 (as of Sep 23, 2026) from 20 valuation models. Cautious scenario $5.36, optimistic scenario $19.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Pro Medicus Limited stock forecast for 2026?
Our models put fair value at $8.94, about −62% upside versus the last price from Sep 25, 2026 of $23.35 (overvalued). Cautious scenario $5.36, optimistic scenario $19.78. The calculation is refreshed regularly with new filings.
What is the revenue of Pro Medicus Limited (PMDIY)?
Pro Medicus Limited reported trailing-twelve-month revenue of about $241M (latest available figure, as of Sep 23, 2026).
Does Pro Medicus Limited pay a dividend?
Pro Medicus Limited currently shows a dividend yield of about 0.36% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Pro Medicus Limited (PMDIY)?
For today's price to be fair in a discounted-cash-flow model, Pro Medicus Limited would have to grow free cash flow by +7.2 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +31.6 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of PMDIY use?
Our models discount Pro Medicus Limited at 8.3 %: a base by market capitalisation (large), damped by beta 0.59, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pro Medicus Limited that is +7.2 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has Pro Medicus Limited (PMDIY) delivered so far?
Over the past 3 years revenue at Pro Medicus Limited grew +31.6 % a year. The price currently implies +7.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pro Medicus Limited (PMDIY) growing?
The median revenue growth in the sector is +2.1 % a year. That is the yardstick for the growth priced into Pro Medicus Limited (+7.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pro Medicus Limited (PMDIY)?
The free-cash-flow yield on the price is 4.26 %: that much free cash flow Pro Medicus Limited produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pro Medicus Limited (PMDIY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pro Medicus Limited it is $8.94 per share (as of Sep 23, 2026), against a price of $23.35. It is the blended result of 20 valuation models (cash flow, earnings, asset, dividend).
Is Pro Medicus Limited stock overvalued or undervalued in 2026?
As of Sep 23, 2026, PMDIY trades above its calculated fair value: price $23.35, fair value $8.94, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PMDIY?
No. The price is what the market pays today ($23.35); the fair value is what the company's own numbers justify ($8.94). For Pro Medicus Limited the two are $14.41 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pro Medicus Limited worth?
The market values Pro Medicus Limited at about $12.3B (market capitalisation, as of Sep 23, 2026). Per share that is $23.35; our models calculate a fair value of $8.94 per share.
What do the bullish and bearish scenarios say about PMDIY?
Our models span a range for Pro Medicus Limited: cautious scenario $5.36, base $8.94, optimistic $19.78 per share (as of Sep 23, 2026, price $23.35). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PMDIY?
Pro Medicus Limited trades at a price-to-earnings ratio of 73.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $8.94 is built from several models across several years. Other multiples: P/B 47.8, P/S 51.0, EV/EBITDA 67.7.
How solid is the balance sheet of Pro Medicus Limited (PMDIY)?
Balance-sheet figures for Pro Medicus Limited (as of Sep 23, 2026): return on equity 76.8%. They feed the Quality Score of 83/100, which measures business quality independently of the share price.
How far is PMDIY from its 52-week high?
Pro Medicus Limited trades at $23.35, about 41% below its 52-week high of $39.87 and 64% above the low of $14.20 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $8.94 is for.
Which stocks are comparable to Pro Medicus Limited?
From the same area (Healthcare) we also value Veeva Systems Inc, BrightSpring Health Services, Inc, Hinge Health, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pro Medicus Limited stock attractive at the current price?
The data as of Sep 23, 2026: price $23.35, calculated fair value $8.94 (−62%), Quality Score 83/100, from 20 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PMDIY calculated?
We run Pro Medicus Limited through 20 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.94, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Pro Medicus Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pro Medicus Limited (PMDIY)?
The latest price we hold is from Sep 25, 2026 and stands at $23.35. Our model-based fair value is $8.94, about −62% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pro Medicus Limited right now?
A high-quality business (quality 83/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case ($19.78). The favourable scenario is already priced in. The model range is unusually wide ($5.36 to $19.78). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Pro Medicus Limited
How large is the market capitalisation of Pro Medicus Limited (PMDIY)?
The market capitalisation of Pro Medicus Limited is $12.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pro Medicus Limited (PMDIY)?
The price-to-sales ratio of Pro Medicus Limited is 39.5 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pro Medicus Limited (PMDIY)?
Earnings per share at Pro Medicus Limited are $0.3200 (price ÷ EPS = P/E 73.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pro Medicus Limited (PMDIY)?
The dividend yield of Pro Medicus Limited is 0.4% (payout 26.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pro Medicus Limited (PMDIY)?
The net margin of Pro Medicus Limited is 54.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pro Medicus Limited (PMDIY)?
The return on equity (ROE) of Pro Medicus Limited is 76.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pro Medicus Limited (PMDIY)?
On an EBIT basis the return on assets of Pro Medicus Limited is 42.8% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pro Medicus Limited (PMDIY)?
The operating margin of Pro Medicus Limited is 72.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pro Medicus Limited (PMDIY)?
Revenue at Pro Medicus Limited is growing +28.4% versus a year earlier (3y avg +31.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pro Medicus Limited (PMDIY)?
Earnings per share at Pro Medicus Limited are growing +231% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Pro Medicus Limited in the live analysis
One click puts Pro Medicus Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 23, 2026